Literature DB >> 11163505

Long-term complications of total body irradiation in adults.

O Thomas1, M Mahé, L Campion, S Bourdin, N Milpied, G Brunet, A Lisbona, A Le Mevel, P Moreau, J Harousseau, J Cuillière.   

Abstract

PURPOSE: To report long-term pulmonary, thyroid, and ocular complications in patients who had conditioning regimens including total body irradiation (TBI) before bone marrow transplantation (BMT). METHODS AND MATERIALS: Between June 1986 and December 1995, 478 patients received TBI in our institution. The present study includes 186 adult patients who had complete remission lasting one year or more after BMT. There were 108 males and 78 females. Median age was 36.5 years (range 15-60). Initial diagnoses were lymphomas (50%), acute lymphoid leukemias (16%), acute myeloid leukemias (16%), chronic myeloid leukemia (13%), aplastic anemia (3%), and myelodysplasia (2%). At the time of BMT, 43.5% of patients were in complete response and 56.5% in partial response. Treatment consisted of a single dose TBI at 10 Gy in 9% and fractionated TBI delivering 12 to 13.5 Gy in 6 fractions in 91%. From 1986 to October 1991, TBI was performed in lateral position with 9 MV energy (57% of patients) and thereafter in alternate prone and supine positions with 15 MV energy (43%). Chemical conditioning regimen was cyclophosphamide (60 mg/kg at D-4 and D-3) in 69% and CBV (cyclophosphamide 1500 mg/m(2) from D-6 to D-3, BCNU 300 mg/m(2) at D-6, VP-16 200 mg/m(2) from D-6 to D-4) in 25%. Fifty eight percent of patients received autologous and 42% allogeneic BMT. All patients had clinical, biologic, and functional examinations at one-year intervals.
RESULTS: Median follow-up from BMT was 49 months (range 12-136). Late pulmonary effects were observed only in functional explorations, without clinical effect, including restrictive syndrome in 8% and alteration in the diffusing capacity of carbon monoxide in 12%. No patient showed clinical thyroid symptoms, and 10% developed biologic dysfunction: hypothyroidism (6.5%), thyroiditis (3%), and Basedow disease (0.5%). Ocular complications occurred in 29.5%, including cataract (15%), dry syndrome (13%), and keratitis (1.5%). In univariate and multivariate analysis, pulmonary complications were statistically increased by chronicle graft vs. host disease (GVHD) vs. no (p = 0.02), prone and supine vs. lateral TBI position (p = 0.02), and with 15 MV vs. 9 MV beam energy (p = 0.02). Cataract occurred less frequently with fractionated than with single-dose TBI (p = 0.000002). No differences were observed regarding age, sex, initial diagnosis, status at the time of BMT, conditioning chemotherapy regimen, and total dose of TBI.
CONCLUSION: From this retrospective study it was shown that long-term complications of TBI were not symptomatic in most patients. The role of parameters of irradiation and especially position of treatment and beam energy should be emphasized and assessed with a longer follow-up.

Entities:  

Mesh:

Year:  2001        PMID: 11163505     DOI: 10.1016/s0360-3016(00)01373-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  31 in total

1.  Modeling of respiratory system dysfunction among nuclear workers: a preliminary study.

Authors:  Z D Belyaeva; S V Osovets; B R Scott; G V Zhuntova; E S Grigoryeva
Journal:  Dose Response       Date:  2008-01-17       Impact factor: 2.658

2.  After the bomb drops: a new look at radiation-induced multiple organ dysfunction syndrome (MODS).

Authors:  Jacqueline P Williams; William H McBride
Journal:  Int J Radiat Biol       Date:  2011-03-21       Impact factor: 2.694

Review 3.  Treatment for radiation-induced pulmonary late effects: spoiled for choice or looking in the wrong direction?

Authors:  Jacqueline P Williams; Carl J Johnston; Jacob N Finkelstein
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

4.  Ethnic differences in chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.

Authors:  Saro H Armenian; Can-Lan Sun; Jennifer Berano Teh; Mukta Arora; K Scott Baker; Liton Francisco; Stephen J Forman; Smita Bhatia
Journal:  Cancer       Date:  2010-09-01       Impact factor: 6.860

5.  Retrospective, monocentric analysis of late effects after Total Body Irradiation (TBI) in adults.

Authors:  Tobias Bölling; David Christoph Kreuziger; Iris Ernst; Hassan Elsayed; Normann Willich
Journal:  Strahlenther Onkol       Date:  2011-04-26       Impact factor: 3.621

6.  Influence of radiation dose rate and lung dose on interstitial pneumonitis after fractionated total body irradiation: acute parotitis may predict interstitial pneumonitis.

Authors:  Natsuo Oya; Keisuke Sasai; Seiji Tachiiri; Takashi Sakamoto; Yasushi Nagata; Takashi Okada; Shinsuke Yano; Takayuki Ishikawa; Takashi Uchiyama; Masahiro Hiraoka
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

7.  Total body irradiation followed by bone marrow transplantation: comparison of once-daily and twice-daily fractionation regimens.

Authors:  Toshinori Soejima; Saeko Hirota; Kayoko Tsujino; Eisaku Yoden; Osamu Fujii; Yukako Ichimiya; Ishikazu Mizuno
Journal:  Radiat Med       Date:  2007-10-26

8.  Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.

Authors:  Scott E James; Nural N Orgun; Thomas F Tedder; Mark J Shlomchik; Michael C Jensen; Yukang Lin; Philip D Greenberg; Oliver W Press
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

9.  Standardized flattening filter free volumetric modulated arc therapy plans based on anteroposterior width for total body irradiation.

Authors:  Rebecca Frederick; Alana Hudson; Alex Balogh; Jeffrey Q Cao; Greg Pierce
Journal:  J Appl Clin Med Phys       Date:  2020-02-11       Impact factor: 2.102

10.  Ocular surface and tear film abnormalities in women under adjuvant chemotherapy for breast cancer with the 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) regimen.

Authors:  A Karamitsos; V Kokkas; A Goulas; P Paraskevopoulos; K Gougoulias; V Karampatakis; K Boboridis
Journal:  Hippokratia       Date:  2013-04       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.